MRI Finds Recurrences in Patients With Rising PSA Level

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 7
Volume 11
Issue 7

ATLANTA-Dynamic magnetic resonance imaging (MRI) may be able to detect recurrent prostate cancer after prostatectomy when the patient has a negative biopsy but a rising prostate-specific antigen (PSA) level.

ATLANTA—Dynamic magnetic resonance imaging (MRI) may be able to detect recurrent prostate cancer after prostatectomy when the patient has a negative biopsy but a rising prostate-specific antigen (PSA) level.

This could potentially spare the patient the need for a second or third biopsy, said Miki Takeda, MD, a radiologist with Sapporo Medical University, Japan. She presented the findings at the 102nd Annual Meeting of the American Roentgen Ray Society (abstract 262).

According to Dr. Takeda, a rising PSA level following radical prostatectomy nearly always means recurrence of cancer. "In our hospital, about 30% of patients have rising PSA levels following radical prostatectomy," she said.

To test the ability of MRI to predict local recurrence, Dr. Takeda and her colleagues evaluated 21 patients with rising PSA levels who had undergone a radical prostatectomy. They examined the prostatic fossa with T2-weighted images. After a bolus injection of a gadolinium contrast agent, multisectional dynamic MR images were obtained every 10 to 15 second for 90 seconds (see Figure).

Although all patients had a negative ultrasound-guided biopsy, MRI suggested local recurrence in 17 of the 21 patients. "In most cases, a second or third biopsy would have been needed to confirm recurrence, and this takes time—time in which the patient’s PSA level may continue to rise," Dr. Takeda said.

Successful Treatment

Fifteen of the 17 patients with suggested local recurrence were treated with radiation therapy. PSA levels gradually declined in 10 of these patients after a 1-year follow-up period, and 7 were subsequently considered cancer free.

"Patients with a low PSA level or a small recurrent tumor before radiation therapy have a very favorable response to radiation," Dr. Takeda pointed out. "MRI has a high enough resolution to detect even a very small local recurrence as reflected by very low PSA levels."

Ultrasound cannot distinguish a fibrotic scar at surgery from a recurrent lesion, she said, but "early phase dynamic MRI can depict a suspicious lesion with first-pass enhancement and can be used in place of a second or third biopsy for any patient, which also lowers the risk of hemorrhage and infection."

In the past, Dr. Takeda said, the urologists in her hospital would hesitate to suggest that these patients undergo radiation therapy until their biopsies came back positive. "Now," she said, " the urologists recommend that these patients begin radiation therapy if their dynamic MR imaging examination indicates a cancer recurrence."

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content